Document And Entity Information [Abstract]
Document Type
Document Type
Document Annual Report
Document Transition Report
Document Period End Date
Document Period End Date
Securities Act File Number
Entity Registrant Name
Entity Registrant Name
Entity Incorporation, State or Country Code
Entity Tax Identification Number
Entity Address, Address Line One
Entity Address, City or Town
Entity Address, State or Province
Entity Address, Postal Zip Code
City Area Code
Local Phone Number
Title of 12(b) Security
Trading Symbol
Security Exchange Name
Entity Well-known Seasoned Issuer
Entity Well-known Seasoned Issuer
Entity Interactive Data Current
Entity Voluntary Filers
Entity Voluntary Filers
Entity Filer Category
Entity Filer Category
Entity Current Reporting Status
Entity Current Reporting Status
Entity Shell Company
Entity Shell Company
Entity Small Business
Entity Small Business
Entity Emerging Growth Company
Entity Emerging Growth Company
ICFR Auditor Attestation Flag
Document Financial Statement Error Correction [Flag]
Entity Public Float
Entity Public Float
Entity Common Stock, Shares Outstanding
Entity Common Stock, Shares Outstanding
Documents Incorporated by Reference [Text Block]
Documents Incorporated by Reference
Auditor Name
Auditor Firm ID
Auditor Location
Entity Central Index Key
Entity Central Index Key
Current Fiscal Year End Date
Current Fiscal Year End Date
Document Fiscal Year Focus
Document Fiscal Year Focus
Document Fiscal Period Focus
Document Fiscal Period Focus
Amendment Flag
Amendment Flag
CONSOLIDATED BALANCE SHEETS
Assets [Abstract]
ASSETS
Assets, Current [Abstract]
CURRENT ASSETS:
Cash and Cash Equivalents, at Carrying Value
Cash and cash equivalents
Accounts Receivable, after Allowance for Credit Loss, Current
Accounts receivable - related party
Contract with Customer, Asset, after Allowance for Credit Loss, Current
Contract assets - related party
Inventory, Net
Inventory
Prepaid Expense, Current
Prepaid expenses
Total prepaid expenses
Income Taxes Receivable
Tax incentive receivable
Other Assets, Current
Other current assets
Assets, Current
Total Current Assets
Property, Plant and Equipment, Net.
Property, plant and equipment, net
Property, plant and equipment, net
Intangible Assets, Net (Excluding Goodwill)
Intangible assets, net
Restricted Cash, Noncurrent
Restricted cash
Other Assets, Noncurrent
Other assets
Equity Method Investments
Equity method and other investments
Operating Lease, Right-of-Use Asset
Right-of-use assets - operating leases, net
Right-of-use asset
Finance Lease, Right-of-Use Asset, after Accumulated Amortization
Right-of-use asset
Right-of-use assets - finance leases, net
Assets
TOTAL ASSETS
Liabilities and Equity [Abstract]
LIABILITIES AND SHAREHOLDERS' (DEFICIT) EQUITY
Liabilities, Current [Abstract]
CURRENT LIABILITIES:
Accounts Payable, Current
Accounts payable
Accrued Liabilities, Current
Accrued expenses
Accrued expenses
Operating Lease, Liability, Current
Lease obligations - operating leases, current
Finance Lease, Liability, Current
Lease obligations - finance leases, current
Deferred Income, Current
Deferred revenue - related party, current
Notes Payable, Current
Note payable, net, current
Other Liabilities, Current
Other current liabilities
Other Liabilities, Current, Total
Liabilities, Current
Total Current Liabilities
Deferred Income, Noncurrent
Deferred revenue - related party
Operating Lease, Liability, Noncurrent
Lease obligations - operating leases
Finance Lease, Liability, Noncurrent
Lease obligations - finance leases
Asset Retirement Obligation
Asset retirement obligations at end of period
Asset retirement obligations at beginning of period
Asset retirement obligations
Notes Payable, Noncurrent
Note payable, net
Liabilities
TOTAL LIABILITIES
Commitments and Contingencies.
COMMITMENTS AND CONTINGENCIES (Note 15)
Equity, Attributable to Parent [Abstract]
SHAREHOLDERS' (DEFICIT) EQUITY:
Common Stock, Value, Issued
Ordinary Shares, $0.00003881 par value, 1,288,327,750 authorized, 81,120,931 and 78,397,380 shares issued and outstanding at December 31, 2025 and 2024, respectively
Additional Paid in Capital
Capital in excess of par value
Accumulated Other Comprehensive Income (Loss), Net of Tax
Accumulated other comprehensive gain (loss)
Retained Earnings (Accumulated Deficit)
Accumulated deficit
Accumulated deficit
Equity, Attributable to Parent
Ending Equity Balance
Beginning Equity Balance
Total Shareholders' (Deficit) Equity
Liabilities and Equity
TOTAL LIABILITIES AND SHAREHOLDERS' (DEFICIT) EQUITY
Common Stock, Par or Stated Value Per Share
Common stock, par value
Common Stock, Shares Authorized
Common stock, shares authorized
Common Stock, Shares, Issued
Common stock, shares issued
Shares issued to related party
Common Stock, Shares, Outstanding
Ending Equity Balance (shares)
Beginning Equity Balance (shares)
Common stock, shares outstanding
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
Statement [Table]
Statement [Table]
Product and Service [Axis]
Product and Service [Domain]
Revenue from related parties earned for services rendered.
Related Party Service Revenue [Member]
Service revenue - related party
License [Member]
License revenue
Statement [Line Items]
Statement [Line Items]
Revenues
Total revenue
Operating Expenses [Abstract]
Operating expenses:
Selling and Marketing Expense
Cost of service revenue - related party
General and Administrative Expense
General and administrative
Research and Development Expense
Research and development
Operating Expenses
Total operating expenses
Total operating expenses
Operating Income (Loss)
Loss from operations
Other Nonoperating Income (Expense) [Abstract]
Other non-operating income (expense):
Gain (Loss), Foreign Currency Transaction, before Tax
Foreign currency (gain) loss
Foreign currency gain (loss)
Investment Income, Interest
Interest income
Interest Expense, Operating and Nonoperating
Interest expense
Amount of gain (loss) on the sale of non-financial assets.
Gain (loss) on sale of nonfinancial assets
Gain on sale of nonfinancial assets
Gain on sale of nonfinancial assets
Net loss
Net loss for the period
Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]
Other comprehensive gain (loss):
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax
Other comprehensive gain (loss)
Foreign currency translation gain (loss)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent
Comprehensive loss
Net Income (Loss) Available to Common Stockholders, Basic
Net loss
Earnings Per Share, Basic
Basic net loss per ordinary share
Earnings Per Share, Diluted
Diluted net loss per ordinary share
Weighted Average Number of Shares Outstanding, Basic
Weighted-average number of ordinary shares outstanding, basic
Weighted Average Number of Shares Outstanding, Diluted
Weighted-average number of ordinary shares outstanding, diluted
CONSOLIDATED STATEMENTS OF SHAREHOLDERS' (DEFICIT) EQUITY
Equity Components [Axis]
Equity Component [Domain]
Common Stock [Member]
Ordinary Shares
Additional Paid-in Capital [Member]
Capital in Excess of Par Value
AOCI Attributable to Parent [Member]
Accumulated Other Comprehensive Loss
Retained Earnings [Member]
Accumulated Deficit
Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture
Exercise of share options and vesting of RSUs
Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture
Exercise of share options and vesting of RSUs (shares)
Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation
Taxes withheld on issuance of share-based awards
Taxes withheld on issuance of share-based awards
Stock Issued During Period, Value, New Issues
Issuance of ordinary shares in at-the-market offering
Stock Issued During Period, Shares, New Issues
Issuance of ordinary shares in at-the-market offering (shares)
Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs
Issuance costs in connection with ordinary shares
Value of stock issued pursuant to a registered offering.
Issuance of shares in connection with registered offering
Issuance of shares in connection with registered offering
Number of shares of stock issued during the period pursuant to registered offerings.
Issuance of shares in connection with registered offering (shares)
Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock in a registered offering.
Issuance costs in connection with registered offering
Issuance costs in connection with registered offering
Value of stock issued pursuant to a private placement offering.
Issuance of shares in connection with private placement offering
Issuance of shares in connection with private placement
Number of shares of stock issued during the period pursuant to private placement offerings.
Issuance of shares in connection with private placement offering (shares)
Issuance of shares in connection with private placement (shares)
CONSOLIDATED STATEMENTS OF CASH FLOWS
Net Cash Provided by (Used in) Operating Activities [Abstract]
Cash flows from operating activities:
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest
Net loss
Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]
Adjustments to reconcile net loss to net cash used in operating activities:
Share-Based Payment Arrangement, Noncash Expense
Share-based compensation
Share-based compensation expense
Depreciation, Depletion and Amortization
Depreciation and amortization
Amount of change in right of use assets.
Change In Right Of Use Assets
Change in right-of-use assets
Gain (Loss) on Termination of Lease
Gain on termination of lease liabilities
Gain (Loss) on Disposition of Property Plant Equipment
Loss on disposal of equipment, furniture and fixtures
Equity Method Investment, Realized Gain (Loss) on Disposal
Loss on equity method investment
Asset Retirement Obligation, Accretion Expense
Amortization of interest on asset retirement obligations
Amortization of Debt Discount (Premium)
Amortization of debt discount
Amount of addition (reduction) to the amount of acquired in-process research and development assets.
Increase Decrease in Acquired In-process Research and Development Assets
Acquired in-process research and development
Increase (Decrease) in Operating Assets [Abstract]
(Increase) decrease in operating assets:
Increase (Decrease) in Accounts Receivable, Related Parties
Accounts receivable - related party
Increase (Decrease) in Contract with Customer, Asset
Contract assets - related party
Increase (Decrease) in Inventories and Other Operating Assets
Inventory
Increase (Decrease) in Prepaid Expense
Prepaid expenses
Increase (Decrease) in Other Receivables
Tax incentive receivable
Increase (Decrease) in Other Current Assets
Other current assets
Increase (Decrease) in Other Noncurrent Assets
Other assets, net
Increase (Decrease) in Operating Liabilities [Abstract]
Increase (decrease) in operating liabilities:
Increase (Decrease) in Accounts Payable
Accounts payable
Increase (Decrease) in Accrued Liabilities
Accrued expenses
Amount of increase (decrease) in lease liabilities.
Change In Lease Liabilities
Change in lease liabilities
Increase (Decrease) in Other Current Liabilities
Other current liabilities
Increase (Decrease) in Deferred Revenue
Deferred revenue - related party
Net Cash Provided by (Used in) Operating Activities
Cash flows from operations
Net cash used in operating activities
Net Cash Provided by (Used in) Investing Activities [Abstract]
Cash flows from investing activities:
Payments to Acquire Property, Plant, and Equipment
Purchase of property, plant and equipment
Payments to Acquire in Process Research and Development
Acquisition of in-process research and development assets
Proceeds from Sale of Property, Plant, and Equipment
Proceeds from sale of equipment, furniture and fixtures
The cash inflow from the gain recognized on the sale of nonfinancial assets.
Proceeds from gain on sale of nonfinancial assets
Proceeds from sale of nonfinancial assets
Net Cash Provided by (Used in) Investing Activities
Net cash (used in) provided by investing activities
Net Cash Provided by (Used in) Financing Activities [Abstract]
Cash flows from financing activities:
Proceeds from Stock Options Exercised
Exercise of share options
Payment, Tax Withholding, Share-Based Payment Arrangement
Payments of withholdings on shares withheld for income taxes
Finance Lease, Principal Payments
Payments on lease obligations - financing leases
Proceeds from Issuance of Common Stock
Proceeds from the issuance of ordinary shares
Aggregate offering price authorized through at-market offerings
Payments of Stock Issuance Costs
Issuance costs in connection with ordinary shares
Offering costs
Net Cash Provided by (Used in) Financing Activities
Net cash provided by financing activities
Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect
Net decrease in cash, cash equivalents and restricted cash
Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations
Effect of exchange rate changes on cash, cash equivalents and restricted cash
Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents
Cash, cash equivalents and restricted cash at end of the year
Cash, cash equivalents and restricted cash at beginning of the year
Total cash, cash equivalents and restricted cash in the condensed consolidated statement of cash flows
Cash, cash equivalents
Noncash Investing and Financing Items [Abstract]
Supplemental disclosure of non-cash transactions:
Asset Acquisition, Consideration Transferred, Contingent Consideration
Fixed asset acquisitions included in accounts payable and accrued expenses
Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
Operating leases
Amount of increase in right-of-use asset obtained in exchange for lease liability.
Right-of-Use Asset Obtained in Exchange for Lease Liability
Right-of-use assets obtained in exchange for lease liabilities
Asset Retirement Obligation, Revision of Estimate
Change in estimate of asset retirement obligation
Change in estimate
The change in issuance costs during the period.
Issuance Cost Reversal
Reversal of issuance costs
Supplemental Cash Flow Information [Abstract]
Supplemental disclosure of cash flow information:
Interest Paid, Excluding Capitalized Interest, Operating Activities
Cash paid for interest
Principal Business Activity
Business Description and Basis of Presentation [Text Block]
Principal Business Activity
Summary of Significant Accounting Policies
Significant Accounting Policies [Text Block]
Summary of Significant Accounting Policies
Equity Method and Other Investments
Equity Method Investments and Joint Ventures Disclosure [Text Block]
Equity Method and Other Investments
Prepaid Expenses
Other Assets Disclosure [Text Block]
Prepaid Expenses
Property, Plant and Equipment, net
Property, Plant and Equipment Disclosure [Text Block]
Property, Plant and Equipment, net
Intangible Assets, net
Intangible Assets Disclosure [Text Block]
Intangible Assets, net
Accrued Expenses
Accounts Payable and Accrued Liabilities Disclosure [Text Block]
Accrued Expenses
Other Current Liabilities
Other Liabilities Disclosure [Text Block]
Other Current Liabilities
Share-Based Compensation
Share-Based Payment Arrangement [Text Block]
Share-Based Compensation
Ordinary Shares
Equity [Text Block]
Ordinary Shares
Income Taxes
Income Tax Disclosure [Text Block]
Income Taxes
Related Party Transactions
Related Party Transactions Disclosure [Text Block]
Related Party Transactions
Leases
Lessee, Operating Leases [Text Block]
Leases
Debt Financing
Debt Disclosure [Text Block]
Debt Financing
Commitments and Contingencies
Commitments Disclosure [Text Block]
Commitments and Contingencies
Employee Benefit Plans
Compensation and Employee Benefit Plans [Text Block]
Employee Benefit Plans
Subsequent Event
Subsequent Events [Text Block]
Subsequent Event
Consolidation, Policy [Policy Text Block]
Consolidation
Use of Estimates, Policy [Policy Text Block]
Use of Estimates
Cash and Cash Equivalents, Policy [Policy Text Block]
Cash and Cash Equivalents
Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]
Restricted Cash
Inventory, Policy [Policy Text Block]
Inventory
Fair Value of Financial Instruments, Policy [Policy Text Block]
Financial Instruments
Regulatory Income Taxes, Policy [Policy Text Block]
Tax Incentive Receivable
Fair Value Measurement, Policy [Policy Text Block]
Fair Value Measurements
Equity Method Investments [Policy Text Block]
Equity Method and Other Investments
Concentration Risk, Credit Risk, Policy [Policy Text Block]
Concentrations of Credit Risk
Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]
Intangible Assets
Property, Plant and Equipment, Policy [Policy Text Block]
Property, Plant and Equipment, Net
Lessee, Leases [Policy Text Block]
Leases
Asset Retirement Obligation [Policy Text Block]
Asset Retirement Obligations
Disclosure of accounting policy for IDA Ireland Grants.
Schedule of Ireland Grants [Policy Text Block]
IDA Ireland Grant
Share-Based Payment Arrangement [Policy Text Block]
Share-Based Compensation Expense
Share-Based Payment Arrangement, Director [Policy Text Block]
Restricted Share Units
Collaborative Arrangement, Accounting Policy [Policy Text Block]
Collaboration Arrangements
Revenue [Policy Text Block]
Revenue Recognition
Research and Development Expense, Policy [Policy Text Block]
Research and Development
Foreign Currency Transactions and Translations Policy [Policy Text Block]
Foreign Currencies
Income Tax, Policy [Policy Text Block]
Income Taxes
Earnings Per Share, Policy [Policy Text Block]
Net Loss per Ordinary Share
Comprehensive Income, Policy [Policy Text Block]
Other Comprehensive Gain (Loss)
Segment Reporting, Policy [Policy Text Block]
Segment Information
Disclosure of accounting policy pertaining to new accounting pronouncements adopted.
Recent Accounting Pronouncements Adopted [Policy Text Block]
Recent Accounting Pronouncements Adopted
New Accounting Pronouncements, Policy [Policy Text Block]
Recent Accounting Pronouncements Not Yet Adopted
Restrictions on Cash and Cash Equivalents [Table Text Block]
Schedule of Restricted Cash
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]
Schedule of Financial Assets and Liabilities Measured at Fair Value
Public Utility Property, Plant, and Equipment [Table Text Block]
Schedule of Estimated Useful Lives of Assets
Schedule of Change in Asset Retirement Obligation [Table Text Block]
Schedule of Change in Asset Retirement Obligations
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]
Schedule of Securities Excluded from Computation of Diluted Net Loss per Share
Schedule of Segment Reporting Information, by Segment [Table Text Block]
Schedule of Net Loss for the Segment
Long-Lived Assets by Geographic Areas [Table Text Block]
Schedule of Long-lived Assets by Geographical Area
Equity Method Investments [Table Text Block]
Schedule of Equity Method and Other Investments
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]
Summary of Prepaid Expenses
Property, Plant and Equipment [Table Text Block]
Schedule of Property, Plant and Equipment, net
Schedule of Finite-Lived Intangible Assets [Table Text Block]
Schedule of Intangible Assets
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]
Schedule of Amortization Expense
Schedule of Accrued Liabilities [Table Text Block]
Schedule of Accrued Expenses
Other Current Liabilities [Table Text Block]
Schedule of Other Current Liabilities
Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]
Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]
Restricted Stock Units (RSUs) [Member]
Restricted Share Units
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-Based Payment Arrangement, Option, Activity [Table Text Block]
Schedule of Share Option Activity
Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]
Schedule of Inputs Used in Determining Fair Value of Share Options
Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]
Schedule of Restricted Share Unit (RSU) Activity
Share-Based Payment Arrangement, Cost by Plan [Table Text Block]
Schedule of Share-Based Compensation Expense
Summary of Operating Loss Carryforwards [Table Text Block]
Summary of Net Operating Loss Carryforwards
Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]
Schedule of Company's Pre-Tax Earnings
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]
Schedule of Reconciliation of Income Tax Benefit with Amounts at the UK Statutory Income Tax Rate
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]
Schedule of Expense/(Benefit) for Income Taxes from Continuing Operations
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]
Schedule of Deferred Tax Assets and Liabilities
Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]
Schedule of Unrecognized Tax Benefits
Related Party Transaction [Table]
Schedule of Related Party Transactions, by Related Party [Table]
Related Party Transaction [Line Items]
Related Party Transaction [Line Items]
Deferred Revenue, by Arrangement, Disclosure [Table Text Block]
Schedule of Deferred Revenue Recognition
Lease, Cost [Table Text Block]
Schedule of Components of Lease Cost
Tabular disclosure of long-lived, depreciable assets that are subject to a lease meeting the criteria for capitalization and are used in the normal conduct of business to produce goods and services. Examples may include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.
Schedule of Amounts Reported in the Consolidated Balance Sheets for Leases [Table Text Block]
Schedule of Amounts Reported in the Consolidated Balance Sheets for Leases
Schedule of Components of Leveraged Lease Investments [Table Text Block]
Schedule of Other Information Related to Leases
Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.
Schedule of Future Minimum Payments Under Non-cancellable Leases [Table Text Block]
Schedule of Future Minimum Payments Under Non-Cancellable Leases
Collaborative Arrangement and Arrangement Other than Collaborative [Table]
Subsequent Event Type [Axis]
Subsequent Event Type [Domain]
Subsequent Event [Member]
Subsequent Event
Statistical Measurement [Axis]
Statistical Measurement [Domain]
Maximum [Member]
Maximum
Counterparty Name [Axis]
Counterparty Name [Domain]
Janssen Pharmaceuticals Inc [Member]
Janssen Pharmaceuticals Inc
Information pertaining to Hologen Limited.
Hologen Limited [Member]
Hologen Limited
Information pertaining to Eli Lilly and Company.
Eli Lilly and Company [Member]
Eli Lilly
Collaborative Arrangement and Arrangement Other than Collaborative [Axis]
Collaborative Arrangement and Arrangement Other than Collaborative [Domain]
Collaborative Arrangement [Member]
Collaboration Agreement
Asset purchase agreement as defined by the Company.
Asset Purchase Agreement [Member]
Asset Purchase Agreement
Collaborative transaction with Hologen Limited.
Hologen Transaction Agreement [Member]
Hologen Strategic Agreement
Manufacturing Framework Agreement with Hologen Limited.
Manufacturing Framework Agreement [Member]
Manufacturing Framework Agreement
Information pertaining to the collaborative agreement with Eli Lilly and Company.
Eli Lilly and Company Collaboration Agreement [Member]
Eli Lilly Collaboration Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestone funding received in collaboration with Hologen Limited.
Milestone funding upfront payment received
Stock issued during period in connection with strategic agreement.
Class A shares of Hologen received in transaction
Additional milestone funding received in collaboration with Hologen Limited.
Additional milestone payment received
Additional funding payment received
Amount of funding receivable on transaction milestones.
Funding Receivable
Funding receivables
Percentage of ownership in company by share class.
Class A share ownership percentage of Hologen Neuro
Percentage of ownership in company by share class.
Class B share ownership percentage of Hologen Neuro
Milestone funding received as additional capital of up to fund the development of the Clinical Programs and the Delivery Device
Milestone funding to provide additional capital
Percentage approval of directors.
Percentage approval of directors
Purchase option after twelve months, percentage of Company's outstanding common shares.
Purchase option after twelve months, percentage of Company's outstanding common shares
Period over which grantee's right to purchase shares under transaction arrangement is no longer effective, and the company's irrevocable option to repurchase shares becomes effective, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.
Repurchase Option, Vesting Period
Vesting period, irrevocable option to purchase shares of MeiraGTx Manufacturing
Funding received from the Company's collaboration agreement with Janssen Pharmaceuticals for the research, development and commercialization of gene therapies for the treatment of inherited retinal diseases..
Collaboration Agreement Funding Received
Initial funding
Maximum contingent funding available under the Company's asset purchase agreement with Janssen Pharmaceuticals.
Contingent funding available
Milestone funding available in other near-term cash consideration upon the achievement of certain development and regulatory approval milestones.
Milestone funding available upon certain development and regulatory approvals
Milestone funding contingent on development and regulatory approval
Funding received from the Company's asset purchase agreement with Janssen Pharmaceuticals.
Asset Purchase Agreement Funding Received
Non-refundable upfront cash funding
Milestone funding received from the Company's collaboration agreement with Janssen Pharmaceuticals.
Milestone Funding Received
Milestone funding
Milestone funding received for the achievement of the initiation of the extension study for the Phase 3 LUMEOS clinical trial for the RPGR Product in connection with the Company's asset purchase agreement with Janssen Pharmaceuticals.
Milestone Funding For Extension of Clinical Trials
Milestone funding for extension of RPGR product clinical trials
Milestone funding received for the completion of certain specified development services for the drug substance for the RPGR Product in connection with the Company's asset purchase agreement with Janssen Pharmaceuticals.
Milestone Funding For Development of Drug Substances
Milestone funding for development of drug substances
Milestone funding received for the completion of certain specified development services for the drug product for the RPGR Product in connection with the Company's asset purchase agreement with Janssen Pharmaceuticals.
Milestone Funding For Development of Drug Products
Milestone funding for development of drug products
Milestone funding received for the first commercial sale of an RPGR Product in the United States in connection with the Company's asset purchase agreement with Janssen Pharmaceuticals.
Milestone Funding For Sale of Drug Products in United States
Milestone funding for sale of drug products in the US
Milestone funding received for the first commercial sale of an RPGR Product in at least one of the United Kingdom, France, Germany, Spain and Italy in connection with the Company's asset purchase agreement with Janssen Pharmaceuticals.
Milestone Funding For Sale of Drug Products in The UK, France, Germany, Spain and Italy
Milestone funding for sale of drug products in the UK, France, Germany, Spain and Italy
Milestone funding received for the transfer of certain manufacturing technology for drug substance and drug product from the Company to Janssen in connection with the Company's asset purchase agreement with Janssen Pharmaceuticals.
Milestone Funding For Transfer of Manufacturing Technology
Milestone funding for transfer of manufacturing technology
Milestone funding received for the regulatory approval of a Janssen-selected manufacturing facility in each of the United States and European Union for commercial manufacture of the RPGR Product in connection with the Company's asset purchase agreement with Janssen Pharmaceuticals.
Milestone Funding For Regulatory Approval
Milestone funding upon regulatory approval
Fair Value, Recurring and Nonrecurring [Table]
Fair Value Measurements, Recurring and Nonrecurring [Table]
Statement of Financial Position Location, Balance [Axis]
Statement of Financial Position Location, Balance [Domain]
Other Current Assets [Member]
Other Current Assets
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
This item represents a receivable for an incentive for taxes. The receivable is due within one year. For classified balance sheets, this element represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.
Tax Incentive Receivable
Research and development tax incentive receivable
Value Added Tax Receivable, Current
VAT receivable
Amount of gain (loss) on provision for obsolete and excess inventory.
Provision Gain (Loss) for Obsolete and Excess Inventory
Provision loss for obsolete and excess inventory
Fair Value Hierarchy and NAV [Axis]
Fair Value Hierarchy and NAV [Domain]
Fair Value, Inputs, Level 1 [Member]
Level 1
Asset Class [Axis]
Asset Class [Domain]
Restricted Cash [Member]
Restricted Cash [Member]
Restricted Cash
Cash and Cash Equivalents [Member]
Cash Equivalents
Maturity period threshold of highly liquid investments classified as cash and cash equivalents, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
Maturity period of highly liquid investments classified as cash and cash equivalents
Fair Value, Net Asset (Liability)
Fair value, net asset (liability)
Property, Plant and Equipment [Table]
Property, Plant and Equipment [Table]
Long-Lived Tangible Asset [Axis]
Long-Lived Tangible Asset [Domain]
Computer Equipment [Member]
Computer and Office Equipment
Other Machinery and Equipment [Member]
Laboratory Equipment
Manufacturing Facility [Member]
Manufacturing Equipment
Furniture and Fixtures [Member]
Furniture and Fixtures
Finite-Lived Intangible Assets by Major Class [Axis]
Finite-Lived Intangible Assets, Major Class Name [Domain]
Licensing Agreements [Member]
Licensed Technology
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life
Property and equipment estimated useful life
Finite-Lived Intangible Assets, Remaining Amortization Period
Intangible assets amortization period
Asset Retirement Obligation, Liabilities Settled
Assignment of leases to Johnson & Johnson Innovative Medicine
Amortization of interest on asset retirement obligation.
Asset Retirement Obligations, Amortization of Interest
Amortization of interest
Asset Retirement Obligation, Foreign Currency Translation Gain (Loss)
Effects of exchange rate changes
Leasehold Improvements, Gross
Leasehold improvements associated with terminated lease
The amount of gain (loss) on release of asset retirement obligation and write-off of leasehold improvements during the period.
Gain (Loss) on Release of Asset Retirement Obligation and Write-Off of Leasehold Improvements
Net gain on writing off the leasehold improvements
Government Assistance [Table]
Government Assistance, Type [Axis]
Government Assistance, Type [Domain]
Represents information pertaining to IDA Ireland grants for financial assistance.
Grants IDA Ireland [Member]
IDA Ireland Financial Assistance Grants
Represents information pertaining to IDA Ireland grants for employment.
Grants IDA Ireland Employment [Member]
IDA Ireland Employment Grants
Represents information pertaining to IDA Ireland grants for capital expenditures.
Grants IDA Ireland Capital [Member]
IDA Ireland Capital Grants
Minimum [Member]
Minimum
Statement of Income Location, Balance [Axis]
Statement of Income Location, Balance [Domain]
Research and Development Expense [Member]
Research and Development Expenses
Government Assistance [Line Items]
Amount of financial assistance available for each new job created.
Grant amount for job creation
Grant funding for each new job created
Amount of financial assistance available for creation of machinery and equipment that provides opportunities for new jobs.
Grant amount for machinery and equipment
Grant funding available for the creation of machinery and equipment that leads to job creation, expressed as a percent of total cost to produce machinery and equipment.
Grants for machinery and equipment as a percentage of total cost to make
Grant amount for machinery and equipment (percent of actual expenditure)
Represents the aggregate number of jobs created in order to be eligible to receive financial assistance under IDA Ireland grants.
Number of new jobs created to receive Grant funding
Aggregate number of new jobs required to receive grant benefits
Financial assistance duration period, measured from the last date of payment received in IDA Ireland grant funding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
Financial Assistance Duration From Last Grant Payment
Termination period (from last grant payment)
Financial assistance duration period, measured from the date in which capital investments for eligible machinery and equipment are completed, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
Financial Assistance Duration From Completion of Capital Investment
Termination period (upon completion of capital investment)
Expenditure requirements on eligible machinery and equipment in order to receive maximum benefits from IDA Ireland financial assistance grants.
Expenditure requirement for grant funding on eligible machinery and equipment
Expenditure requirement on eligible machinery and equipment
Amount of funding received from IDA Ireland grants.
Grant funding received
Amount of funding received from IDA Ireland grants and recognized as income to offset research and development expenses.
Grant funding recognized as income
Recognized grant income
Period benchmark in which the Company may be held to repay a portion of capital grants if a job for which the Company received employment grant funding remains vacant, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
Period of job vacancy before grant funding becomes repayable
Vacant job duration prompting repayment of grant funding
Revenue Recognition, Milestone Method [Table]
Related and Nonrelated Parties [Axis]
Related and Nonrelated Parties [Domain]
Revenue Recognition, Milestone Method [Line Items]
The percentage of expenses incurred by the Company and reimbursable from related parties.
Percentage of expenditures reimbursable from related parties
Percentage of incurred R&D costs to be reimbursed by third parties
Income Tax Contingency [Table]
Income Tax Contingency [Line Items]
Unrecognized Tax Benefits
Unrecognized tax benefits, ending balance
Unrecognized tax benefits, beginning balance
Unrecognized tax positions
Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued
Unrecognized tax benefits, income tax penalties and interest accrued
Antidilutive Security, Excluded EPS Calculation [Table]
Antidilutive Securities [Axis]
Antidilutive Securities, Name [Domain]
Warrant [Member]
Warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
Anti-dilutive securities excluded from EPS
Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.
Service revenue from related parties
Service revenue - related party
Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.
License revenue from related parties
License revenue - related party
License revenue
The segment total of research and development expenses.
Segment general and administrative expenses
General and administrative
Amount of expense for clinical trials for Botaretigene Sparoparvovec drug substances.
Clinical Programs Drug Product 1
Botaretigene sparoparvovec
Amount of expense for clinical trials for AAV-hAQP1 drug substances.
Clinical Programs Drug Product 2
AAV-hAQP1
Amount of expense for clinical trials for AAV-CNGB3 / AAV-CNGA3 drug substances.
Clinical Programs Drug Product 3
AAV-CNGB3 / AAV-CNGA3
Amount of expense for clinical trials for AAV-GAD drug substances.
Clinical Programs Drug Product 4
AAV-GAD
Amount of expense for research and development pertaining to clinical trials for drug substances.
Research and development clinical trials
Other ocular diseases
Amount of expense for research and development pertaining to manufacturing of drug substances.
Research and development Manufacturing
Manufacturing
Amount of expense for pre-clinical research relating to gene regulation.
Pre-clinical research Gene Regulation
Gene regulation
Amount of expense for pre-clinical research relating to neurodegenerative diseases.
Pre-clinical research Neurodegenerative Diseases
Neurodegenerative diseases
Amount of expense for pre-clinical research relating to preclinical ocular diseases.
Pre-clinical research Preclinical Ocular Diseases
Preclinical ocular diseases
Amount of expense for research and development classified as other.
Research and development other
Other research and development
Other segment items of income (expense).
Other segment items income statement
Other segment items
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Segment net income (loss)
Segment net loss
Number of Reportable Segments
Number of reportable segments
Number of Operating Segments
Number of operating segments
Schedule of Revenues from External Customers and Long-Lived Assets [Table]
Geographical [Axis]
Geographical [Domain]
UNITED STATES
United States
UNITED KINGDOM
United Kingdom
European Union [Member]
EUROPEAN UNION
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-Lived Assets
Non-current assets
Equity Method Investment [Table]
Investment, Name [Axis]
Investment, Name [Domain]
Represents information pertaining to Visiogene LLC.
Visiogene LLC
Represents information pertaining to equity method investments other than Visogene LLC.
Other Investments
Schedule of Equity Method Investments [Line Items]
Equity Method and Other Investments
Equity Method Investment, Ownership Percentage
Equity ownership in outstanding ordinary shares
Ownership percentage
Equity Method Investment, Quoted Market Value
Carrying Value
Equity Method Investment, Aggregate Cost
Cost Basis
Represents information relating to License and Investment Agreement with Visiogene LLC.
Visiogene License Agreement
Represents information relating to Visiogene Unit Agreement.
Visiogene Unit Agreement
Number of preferred units acquired under the license and investment agreement.
License And Investment Agreement, Number Of Preferred Units Acquired
Number of preferred units acquired
Payments to Acquire Investments
Cash consideration
Stock issued during period shares per license agreement.
Stock Issued During Period Shares License Agreement
Ordinary shares issued in connection with a license agreement (in shares)
Stock Issued During Period Value License Agreement
Stock Issued During Period Value License Agreement
Value of shares issued
Amount of payment to acquire investment allocated as a basket transaction.
Payments To Acquire Investments Allocation
Allocation of payments
Investment allocated as a basket transaction expensed during the period.
Investments Allocated Amount Expensed
Investment allocated amount expensed
The carrying value as on the balance sheet date of prepaid manufacturing costs.
Prepaid Manufacturing Costs Current
Manufacturing costs
Prepaid dues and license fees.
Prepaid Dues and License Fees
Dues and license fees
Prepaid Insurance
Insurance
Prepaid Rent
Facilities costs
Prepaid Clinical Trial Cost
Prepaid Clinical Trial Cost
Clinical trial costs
Other Prepaid Expense, Current
Other
Leasehold Improvements [Member]
Leasehold Improvements
Property, Plant and Equipment, Gross
Property, plant and equipment, gross
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment
Less: Accumulated depreciation
Depreciation, Depletion and Amortization, Nonproduction
Depreciation and amortization expense
Amount of physical assets used in the normal conduct of business to produce goods and services and not intended for resale, that are not subject to depreciation.
Property, Plant and Equipment, Not Subject to Depreciation
Property, plant and equipment, not subject to depreciation
Intangible Asset, Finite-Lived [Table]
Technology-Based Intangible Assets [Member]
Licensed Technology
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross
Gross Carrying Amount
Finite-Lived Intangible Assets, Accumulated Amortization
Less: Accumulated Amortization
Finite-Lived Intangible Assets, Net
Total
Finite-Lived Intangible Assets Acquired
Upfront payment for intangible assets
Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life
Intangible assets amortization period
Amortization of Intangible Assets
Intangible asset amortization
Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]
Amortization expense
Finite-Lived Intangible Asset, Expected Amortization, Year Two
2026
Finite-Lived Intangible Asset, Expected Amortization, Year Three
2027
Accrued Liabilities Accrued Compensation And Benefits
Accrued Liabilities Accrued Compensation And Benefits
Compensation and benefits
Accrued Professional Fees, Current
Professional fees
Accrued Research And Development
Accrued Research And Development
Research and development
Accrued Liabilities Accrued Manufacturing Costs Expense.
Accrued Liabilities Accrued Manufacturing Costs Expense
Manufacturing costs
Deposit Liabilities, Accrued Interest
Interest on Tranche 1 Notes
Accrued Clinical Trial Costs
Accrued Clinical Trial Costs
Clinical trial costs
Other Accrued Liabilities, Current
Other
Amount of upfront payment liabilities, due within one year or the normal operating cycle, if longer.
Upfront Payment Liabilities, Current
Hologen Limited Upfront Payments
Other Sundry Liabilities, Current
Other
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]
Number of Options
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number
Number of options, Ending balance
Number of options, Beginning balance
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross
Number of options, Granted
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period
Number of options, Exercised
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period
Number of options, Forfeited
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]
Weighted-Average Exercise Price
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price
Weighted-average exercise price, Ending balance
Weighted-average exercise price, Beginning balance
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
Weighted-average exercise price, Granted
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price
Weighted-average exercise price, Exercised
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price
Weighted-average exercise price, Forfeited
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]
Options additional disclosures
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number
Number of options, Options exercisable
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price
Weighted-average exercise price, Options exercisable
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term
Weighted-average remaining contractual life of options, outstanding
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term
Weighted-average remaining contractual life of options, exercisable
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number
Number of options, Options vested and expected to vest
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price
Weighted-average exercise price, Options vested and expected to vest
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term
Weighted-average remaining contractual life, Options vested and expected to vest
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value
Aggregate intrinsic value, options outstanding
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value
Aggregate intrinsic value, options exercisable
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum
Risk-free interest rate, minimum
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum
Risk-free interest rate, maximum
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate
Expected volatility
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate
Expected dividend yield
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term
Expected term (in years)
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Number of restricted share units
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number
Number of restricted share units, Ending balance
Number of restricted share units, Beginning balance
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period
Number of restricted share units, Granted
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period
Number of restricted share units, Vested
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period
Number of restricted share units, Forfeited
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Weighted-average grant date fair value
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value
Weighted-average grant date fair value, Ending balance
Weighted-average grant date fair value, Beginning balance
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value
Weighted-average grant date fair value, Granted
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value
Weighted-average grant date fair value, Vested
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value
Weighted-average grant date fair value, Forfeited
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]
General and Administrative Expense [Member]
General and Administrative Expense
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-Based Payment Arrangement, Expense
Total share-based compensation
Vesting [Axis]
Vesting [Domain]
First Anniversary [Member]
First Anniversary [Member]
First Anniversary
Second Anniversary member
Second Anniversary [Member]
Second Anniversary
Third anniversary member
Third Anniversary [Member]
Third Anniversary
Fourth Anniversary member
Fourth Anniversary [Member]
Fourth Anniversary
Over Three Years Member
Over Three Years [Member]
Over Three Years
Grantee Status [Axis]
Grantee Status [Domain]
Director [Member]
Directors
Plan Name [Axis]
Plan Name [Domain]
Information pertaining to the Company's 2018 equity incentive award plan.
2018 Incentive Award Plan
The annual percent increase in available shares under equity incentive plans.
Annual percent increase in available shares under equity incentive plan
Annual percent increase in available shares under equity incentive plan
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized
Shares reserved for issuance
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant
Shares available for future issuance
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized
Additional shares reserved for issuance
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage
Vesting percentage
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period
Vesting period
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value
Fair value of options, Vested
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
Weighted-average grant date fair value of options granted
Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount
Total unvested options compensation expense not yet recognized
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition
Period expected to realize unrecognized compensation expense
The number of shares that have fully vested and have been deferred.
Vested shares deferred
Shares vested and deferred
Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation
Ordinary shares withheld for statutory tax requirements
Amount of cash outflow for realized tax benefit related to deductible compensation cost reported on the entity's tax return for equity instruments in excess of the compensation cost for those instruments recognized for financial reporting purposes.
Excess Tax Benefit from Share-based Compensation, Operating Activities1
Excess tax benefits in cash flows from operations
Amount of cash inflow from realized tax benefit related to deductible compensation cost reported on the entity's tax return for equity instruments in excess of the compensation cost for those instruments recognized for financial reporting purposes.
Excess Tax Benefit from Share-based Compensation, Financing Activities1
Excess tax benefits in cash flows from financing activities
Share Price
Common stock share price
Stock, Class of Stock [Table]
Information pertaining to BofA Securities, Inc.
Bank of America Securities, Inc. [Member]
B of A Securities, Inc.
Information pertaining to an accredited investor for which the Company issued shares to in a private placement agreement.
Accredited Investor [Member]
Accredited Investor
Information pertaining to the at-the-market sales agreement to sell shares of the Company's common stock.
Sales Agreement [Member]
At-The-Market Sales Agreement
Information pertaining to the Equity Financing Agreement.
Equity Financing [Member]
Equity Financing Agreement
Sale of Stock [Axis]
Sale of Stock [Domain]
It represents the information pertaining to the ATM offering.
At-the-market Offering
Public Offering
Private Placement [Member]
Private Placement
Class of Stock [Line Items]
Sale of Stock, Consideration Received Per Transaction
Gross proceeds from sale of ordinary shares
Sale of Stock, Number of Shares Issued in Transaction
Ordinary shares issued in transaction
Sale of Stock, Price Per Share
Common stock, price per share
Share price of ordinary shares issued
Floor Brokerage, Exchange and Clearance Fees
Underwriting discounts and commissions
Operating Loss Carryforwards [Table]
Operating Loss Carryforwards [Line Items]
Income Tax Expense (Benefit)
Actual income tax benefit effective tax rate
Provision recorded for income tax expense (benefit)
Income Tax Jurisdiction [Axis]
Income Tax Jurisdiction [Domain]
Domestic Tax Jurisdiction [Member]
Federal
Foreign Tax Jurisdiction [Member]
Foreign Tax Jurisdiction
Represents information pertaining to federal tax jurisdiction for the foreign country United States.
Income Tax Jurisdiction, Foreign Federal, United States [Member]
United States, Federal
Represents information pertaining to state and local tax jurisdiction for the foreign country United States.
Income Tax Jurisdiction, Foreign State And Local, United States [Member]
United States, State/City
IRELAND
Ireland
Foreign Tax Jurisdiction, Other [Member]
Other
Tax Credit Carryforward [Axis]
Tax Credit Carryforward, Name [Domain]
Research Tax Credit Carryforward [Member]
Research and Development Tax Credits
Investment Tax Credit Carryforward [Member]
Orphan Drug Tax Credit
Operating Loss Carryforwards
NOL carryforwards
Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws which is subject to expiration.
Operating Loss Carryforwards, Subject To Expiration
Carryforward tax losses, subject to expiration
Tax Credit Carryforward, Amount
Tax credit carryforwards
Income (Loss) from Continuing Operations before Income Taxes, Domestic
Pre-tax income (loss), Domestic
Income (Loss) from Continuing Operations before Income Taxes, Foreign
Pre-tax income (loss), Foreign
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest
Loss before income taxes
Income Taxes Paid, Net
Income taxes paid net of refunds received
Effective Income Tax Rate Reconciliation [Table]
Effective Income Tax Rate Reconciliation [Line Items]
Income Taxes
Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract]
Reconciliation, amount:
Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount
Statutory rate
Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount
Statutory tax rate difference between United States and United Kingdom
Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount
State and Local Income Taxes, Net of Federal Income Tax Effect
Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount
RTP and other adjustment
Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to compensation limitation adjustment under Section 162 (m) of the Act.
Effective Income Tax Rate Reconciliation, Compensation Limitation Adjustment, Amount
Section 162(m) Adj.
Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Amount
Share based compensation shortfall
Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount
U.S. state rate change
Effective Income Tax Rate Reconciliation, Tax Credit, Amount
Tax Credits
Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount
Change in valuation allowance
Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount [Abstract]
Nontaxable or Nondeductible Items
Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible interest expense.
Effective Income Tax Rate Reconciliation, Nondeductible Expense, Interest, Amount
Nondeductible interest
Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount
Disallowed interest
Effective Income Tax Rate Reconciliation, Other Adjustments, Amount
Other Adjustments
Tax Jurisdiction of Domicile [Extensible Enumeration]
Effective Income Tax Rate Reconciliation, Percent [Abstract]
Reconciliation, percent:
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent
Statutory rate
Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent
Statutory tax rate difference between United States or Other Foreign Countries and United Kingdom
Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent
State and local rate, net of federal tax
Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent
Research and development tax credits
Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to compensation limitation adjustment under Section 162 (m) of the Act.
Effective Income Tax Rate Reconciliation, Compensation Limitation Adjustment, Percent
Section 162(m) Adj.
Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Percent
Share based compensation shortfall
Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent
U.S. state rate change
Effective Income Tax Rate Reconciliation, Tax Credit, Percent
Tax Credits
Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent
Change in valuation allowance
Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent [Abstract]
Nontaxable or Nondeductible Items
Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to interest expense.
Effective Income Tax Rate Reconciliation, Nondeductible Expense, Interest, Percent
Nondeductible interest
Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent
Other
Effective Income Tax Rate Reconciliation, Other Adjustments, Percent
Permanent differences - other
Effective Income Tax Rate Reconciliation, Percent
Effective income tax rate
Actual income tax benefit effective tax rate
Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]
Deferred Tax Expense/(Benefit)
Deferred Federal, State and Local, Tax Expense (Benefit)
Federal deferred tax expense/(benefit)
Deferred Foreign Income Tax Expense (Benefit)
Foreign deferred tax expense/(benefit)
Deferred Income Tax Expense (Benefit)
Deferred tax expense (benefit)
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
Change in Valuation Allowances
Deferred Tax Assets, Net [Abstract]
Deferred Tax Assets:
Deferred Tax Assets, Operating Loss Carryforwards
Net operating loss carryforwards
Deferred Tax Asset, Interest Carryforward
Interest expense
Deferred Tax Asset, In-Process Research and Development
Capitalized research and development
Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost
Share-based compensation
Deferred Tax Assets, Tax Credit Carryforwards
R&D credit
Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Deferred Rent
Lease liability
Deferred Tax Assets, Gross
Deferred tax assets
Deferred Tax Assets, Valuation Allowance
Less: valuation allowance
Deferred Tax Liabilities, Net [Abstract]
Deferred Tax Liabilities:
Deferred Tax Liabilities, Property, Plant and Equipment
Depreciation
Deferred Tax Liabilities, Leasing Arrangements
Right of use assets
Deferred Tax Liabilities, Other
Other
Deferred Tax Liabilities, Net
Net deferred tax liability
Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions
Gross increases/(decreases) related to current year
Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions
Gross increases/(decreases) related to prior years
Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions
Gross increases/(decreases) related to prior years
Income Tax, Examination [Table]
Income Tax Examination [Line Items]
Income Tax Examination, Description
Income tax examination
Pertaining to JJDC - the investment arm of Johnson & Johnson and owner of Janssen.
JJDC
License agreement with Jannsen Pharmaceuticals pertaining to services, material rights representing the commercial supply of RPGR Product and an in-substance contract renewal option, manufacturing technology transfer, and the sale of nonfinancial assets representing the sale and transfer of all the Company's right, title, and interest in the intellectual property related to the RPGR Product.
License Agreement UCLB RPGR [Member]
UCLB RPGR License Agreement
Other Operating Income (Expense) [Member]
Other Income
Primary financial statement caption encompassing revenue from sale of goods and services rendered in the normal course of business.
Service revenue - related party [Member}
Service revenue - related party
Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.
Deferred revenue recognized during period
Deferred revenue recognized as service revenue during the period
Deferred revenue recognized as service revenue during the period
Initial duration period of the asset purchase agreement.
Initial Agreement Period Duration
Initial agreement term
Days of written notice needed in order to terminate the asset purchase agreement.
Agreement Termination Period Days Written Notice
Written days-notice to terminate agreement
Related-party deferred revenue reclassified under provisions of new license agreement.
Related-party deferred revenue reclassified
Deferred revenue - related party included in contract price of license agreement
Variable consideration included in provisions of new license agreement.
Variable consideration for services
Variable consideration for services included in contract price of license agreement
Initial funding received under Asset Purchase Agreement reclassified under provisions of new license agreement.
Asset purchase agreement funding reclassified
Asset purchase agreement funding included in contract price of license agreement
Total contract price of license agreement.
Contract price of license agreement
Offsetting credit for transition services in determining contract price under license agreement.
Offsetting credit for transition services
License agreement contract price allocated to performance obligation for process performance qualification (PPQ) services.
Performance obligation for process performance qualification services
License agreement contract price allocated to performance obligation for commercial supply of RPGR product.
Performance obligation for commercial supply of RPGR product
License agreement contract price allocated to performance obligation for manufacturing technology transfer.
Performance obligation for manufacturing technology transfer
License agreement contract price allocated to performance obligation for sale of nonfinancial assets.
Performance obligation for sale of nonfinancial assets
Milestone funding received and allocated to performance obligation for process performance qualification (PPQ) services.
Milestone funding allocated to process performance qualification services
Milestone funding received and allocated to performance obligation for commercial supply of RPGR product.
Milestone funding allocated to commercial supply of RPGR product
Milestone funding received and allocated to performance obligation for manufacturing technology transfer.
Milestone funding allocated to manufacturing technology transfer
Milestone funding received and allocated to performance obligation for sale of nonfinancial assets.
Milestone funding allocated to sale of nonfinancial assets
Amount of income recognized from deferred related-party revenues.
Recognized related-party deferred revenue
Deferred revenue - related party recognized
Amount of transaction price allocated to performance obligation that has not been recognized as revenue.
Revenue, unsatisfied performance obligation, amount
Deferred revenue, unsatisfied performance obligations
Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
Revenue, unsatisfied performance obligation, expected recognition period
Recognition period for deferred revenue, unsatisfied performance obligations
Information pertaining to Perceptive Advisors, LLC.
Perceptive Advisors, LLC
Information pertaining to the financing agreement with Perceptive Advisors, LLC.
Secured Financing Agreement
Notes Purchase Agreement
Share Repurchase Program [Axis]
Share Repurchase Program [Domain]
Represents the information pertaining to share repurchases agreement with Perceptive Life Sciences Master Fund, Ltd.
Share Repurchase Agreement with Perceptive Life Sciences Master Fund, Ltd [Member]
Perceptive Life Sciences Master Fund, Ltd.
Share Repurchase Program, Authorized, Number of Shares
Number of shares repurchased
Share Repurchase Program, Authorized, Amount
Aggregate purchase price
Amount payable on share purchased under share repurchase plan.
Share Repurchase Program, Liability
Liability recognized
Contract with Customer, Liability
Deferred revenue at period-end
The amount of milestone payments collected or invoiced, categorized as other.
Contract with Customer, Liability, Other Amounts Collected or Invoiced
Other amounts collected or invoiced
The effect of exchange rates on customer contract liability.
Contract With Customer Liability Effect Of Exchange Rate
Effects of exchange rate changes
Finance Lease, Right-of-Use Asset, Amortization
Amortization of right-of-use assets
Finance Lease, Interest Expense
Interest on lease liabilities
Variable Lease, Cost
Total finance lease cost
Operating Lease, Cost
Operating lease cost
Short-Term Lease, Cost
Short-term lease cost
Lease, Cost
Total lease cost
Operating Lease [Abstract]
Operating Lease [Abstract]
Operating leases
Operating Lease, Liability
Capitalized lease obligations
Operating lease liability
Finance Lease [Abstract]
Finance Lease [Abstract]
Finance leases
Finance Lease, Liability
Capitalized lease obligations
Finance lease liability
Weighted Average Remaining Lease Term [Abstract]
Weighted Average Remaining Lease Term [Abstract]
Weighted-average remaining lease term
Operating Lease, Weighted Average Remaining Lease Term
Operating leases
Finance Lease, Weighted Average Remaining Lease Term
Finance leases
Weighted Average Discount Rate [Abstract]
Weighted Average Discount Rate [Abstract]
Weighted-average discount rate
Operating Lease, Weighted Average Discount Rate, Percent
Operating leases
Finance Lease, Weighted Average Discount Rate, Percent
Finance leases
Cash paid for amounts included in measurement of lease liabilities [Abstract]
Cash Paid For Amounts Included In Measurement Of Lease Liabilities [Abstract]
Cash paid for amounts included in the measurement of lease liabilities
Operating Lease, Payments
Operating cash flows from operating leases
Amount of cash outflow from finance lease.
Finance Lease Payments
Financing cash flows from finance leases
Right of Use Assets Obtained in Exchange for Lease Obligations [Abstract]
Right Of Use Assets Obtained in Exchange For Lease Obligations [Abstract]
Right-of-use assets obtained in exchange for lease liabilities
Right-of-Use Asset Obtained in Exchange for Finance Lease Liability
Finance leases
Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]
Lessee, Operating Lease, Liability, to be Paid, Year One
2026
Lessee, Operating Lease, Liability, to be Paid, Year Two
2027
Lessee, Operating Lease, Liability, to be Paid, Year Three
2028
Lessee, Operating Lease, Liability, to be Paid, Year Four
2029
Lessee, Operating Lease, Liability, to be Paid, Year Five
2030
Lessee, Operating Lease, Liability, to be Paid, after Year Five
Thereafter
Lessee, Operating Lease, Liability, to be Paid
Total undiscounted lease payments
Lessee, Operating Lease, Liability, Undiscounted Excess Amount
Less: Imputed interest
Finance Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]
Finance Lease, Liability, to be Paid, Year One
2026
Finance Lease, Liability, to be Paid, Year Two
2027
Finance Lease, Liability, to be Paid, Year Three
2028
Finance Lease, Liability, to be Paid, Year Four
2029
Finance Lease, Liability, to be Paid
Total undiscounted lease payments
Finance Lease, Liability, Undiscounted Excess Amount
Less: Imputed interest
Lessee, Lease, Description [Table]
Land and Building [Member]
New Leases
Represents information pertaining to building one.
Building one
Laboratory Space
Represents information pertaining to building two.
Building two
Office Space
Lessee, Lease, Description [Line Items]
Lease Maturity Term
Lease Maturity Term
Lease term
Operating Lease, Expense
Operating lease rent expenses
Lessee, Operating Lease, Term of Contract
Operating lease, term of contract
The number new leases recognized during the period.
Operating Lease Number New Leases Recognized
New leases recognized during period
Line of Credit Facility [Table]
Lender Name [Axis]
Line of Credit Facility, Lender [Domain]
Information pertaining to the financing agreement with Perceptive Credit Holdings..
Perceptive Credit Holdings
Debt Instrument [Axis]
Debt Instrument, Name [Domain]
Secured Debt [Member]
Secured Debt
Credit Facility [Axis]
Credit Facility [Domain]
Term loans granted under the Company's financing agreement.
Term Loan
Variable Rate [Axis]
Variable Rate [Domain]
Base Rate [Member]
Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member]
SOFR
Scenario [Axis]
Scenario [Domain]
Information related to warrants to buy common shares with various exercise prices.
Exercise Price - Scenario I
Information related to warrants to buy common shares with various exercise prices.
Exercise Price - Scenario II
Line of Credit Facility [Line Items]
Debt Instrument, Face Amount
Initial face amount
Debt Instrument, Unused Borrowing Capacity, Amount
Unused borrowing capacity
Portion of the principal amount, agreed to redeem.
Debt Instrument, Principal Amount, Amount to Redeem
Portion of the principal amount, agreed to redeem
Debt Instrument, Interest Rate, Stated Percentage
Stated interest rate
Period of time between changes in the offered SOFR rate, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
Secured Overnight Financing Rate, Adjustment Term
SOFR adjustment term
Floor percentage for basis points added to the reference rate to compute the variable rate on the debt instrument.
Basis Spread on Variable Rate Floor
Floor percentage
Long-Term Debt, Weighted Average Interest Rate, at Point in Time
Interest rate at period-end
Secured Debt, Current
Term loan outstanding amount
Debt Instrument, Increase, Accrued Interest
Increase in accrued interest
Interest Expense, Debt
Interest expense on debt
Guaranteed Benefit Liability, Net
Obligations secured by UK and Ireland subsidiaries
Liquidity requirement for minimum amount of cash and bank accounts to be maintained and secured under the financing agreement with Perceptive Credit Holdings.
Cash liquidity requirement
Shares available for purchase in connection with the financing agreement with Perceptive Credit Holdings.
Shares Issued In Connection With Financing Agreement
Shares available through warrants
Class of Warrant or Right, Exercise Price of Warrants or Rights
Warrant exercise price
Common Stock, Discount on Shares
Debt discount, allocated fair value of warrants
Debt Issuance Costs, Net
Debt discount, capitalized issuance costs
Debt Instrument, Unamortized Discount
Unamortized debt discount
Other Commitments [Table]
Other Commitments [Table]
Other Commitments [Line Items]
Other Commitments [Line Items]
Loss Contingency, Damages Sought, Value
Total potential benefit associated with the filed claims
Retirement Benefits [Abstract]
Compensation And Retirement Disclosure [Table]
Compensation And Retirement Disclosure [Table]
Compensation And Retirement Disclosure [Table]
BELGIUM
Compensation And Retirement Disclosure [Line Items]
Compensation And Retirement Disclosure [Line Items]
Compensation And Retirement Disclosure [Line Items]
Amount of contribution received by defined benefit plan from employer which increases plan assets.
Defined benefits plan, plan assets, contributions by employer
Defined contribution plan employee eligibility age.
Defined Contribution Plan Employee Eligibility Age
Defined contribution plan, employee eligibility age
Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.
Defined contribution plan, annual contributions per employee, percent
Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.
Defined Benefit plan, employer matching contribution, percent
Percentage of employer contribution exclusive of the employee's match contribution.
Defined Contribution Plan, Employer Contribution Exclusive Of Employee Match, Percent
Defined contribution plan, employer contribution exclusive of employee match, percent
Subsequent Event [Table]
Subsequent Event [Table]
Subsequent Event [Line Items]
Subsequent Event [Line Items]
Gross amount of debt agreed to redeem.
Debt Instrument, Redemption, Agreed To Redeem Amount
Debt, agreed to redeem amount
Information pertaining to Alexandria Forbes, Ph. D., MeiraGTx's President and Chief Executive Officer.
Alexandria Forbes, Ph.D.
Alexandria Forbes
Information pertaining to Richard Giroux, MeiraGTx's Chief Financial Officer and Chief Operating Officer.
Richard Giroux
Information pertaining to Stuart Naylor, MeiraGTx's Chief Development Officer.
Stuart Naylor [Member]
Stuart Naylor